Who are nifedipine controlled release tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Amlodipine+intensive antihypertensive therapy, Amlodipine+Benazepril, Calcium Channel Blockers, Lercanidipine/enalapril fixed combination, Amlodipine (Norvasc), Telmisartan + Amlodipine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nifedipine-controlled-release-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

nifedipine controlled release tablets — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

nifedipine controlled release tablets (nifedipine controlled release tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker (dihydropyridine). Area: Cardiovascular.

marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

nifedipine controlled release tablets (nifedipine controlled release tablets) — Guangzhou First People's Hospital. Nifedipine is a calcium channel blocker that reduces calcium influx into vascular smooth muscle and cardiac cells, causing vasodilation and decreased blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
nifedipine controlled release tablets TARGET	nifedipine controlled release tablets	Guangzhou First People's Hospital	marketed	Calcium channel blocker (dihydropyridine)	L-type voltage-gated calcium channel
Amlodipine+intensive antihypertensive therapy	Amlodipine+intensive antihypertensive therapy	Beijing Tiantan Hospital	marketed	Calcium channel blocker (dihydropyridine)	L-type voltage-gated calcium channel
Amlodipine+Benazepril	Amlodipine+Benazepril	TSH Biopharm Corporation Limited	marketed	Calcium channel blocker + ACE inhibitor combination	L-type voltage-gated calcium channels; Angiotensin-converting enzyme (ACE)
Calcium Channel Blockers	Calcium Channel Blockers	Hospital de Clinicas de Porto Alegre	marketed	Calcium channel blocker	L-type voltage-gated calcium channel
Lercanidipine/enalapril fixed combination	Lercanidipine/enalapril fixed combination	Meir Medical Center	marketed	Calcium channel blocker / ACE inhibitor combination	L-type voltage-gated calcium channels; Angiotensin-converting enzyme (ACE)
Amlodipine (Norvasc)	Amlodipine (Norvasc)	Bayer	marketed	Calcium channel blocker (dihydropyridine)	L-type voltage-gated calcium channel
Telmisartan + Amlodipine	Telmisartan + Amlodipine	Daewon Pharmaceutical Co., Ltd.	marketed	Angiotensin II receptor blocker + Calcium channel blocker combination	AT1 receptor (angiotensin II type 1 receptor) and L-type voltage-gated calcium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker (dihydropyridine) class)

Bayer · 2 drugs in this class
Beijing Tiantan Hospital · 2 drugs in this class
GlaxoSmithKline · 1 drug in this class
Guangzhou First People's Hospital · 1 drug in this class
Organon and Co · 1 drug in this class
Peking University First Hospital · 1 drug in this class
Pfizer Inc. · 1 drug in this class
SK Chemicals Co., Ltd. · 1 drug in this class
Shanghai Jiao Tong University School of Medicine · 1 drug in this class
Shanghai Shyndec Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). nifedipine controlled release tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/nifedipine-controlled-release-tablets. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing